In 1998, Dr. Ted Johnson, co-founder of the Pediatric Immunotherapy Program at the Medical College of Georgia at Augusta University, and a team of doctors discovered that cancerous tumors manipulate the enzyme indoleamine 2, 3-dioxygenase (IDO) in order to bypass the body’s immune system. This discovery has led to the homegrown therapy drug Indoximod, a form of immunotherapy that blocks the IDO enzyme that is being used to treat a rare form of brain cancer in children.
“I can’t say that this treatment is effective at this point,” said Johnson. “We haven’t enrolled enough patients, we haven’t treated enough patients and we’re in the very, very earliest phases of treating any DIPG patients. But if it works at all, it is likely to work across several tumor types that occur in kids.”
The Augusta Chronicle: Drug therapy discovered at MCG being used to treat rare form of brain cancer in children
Jan. 14, 2018